Nancy M. Bennett
A5078442226- Influenza Virus Research Studies
- Respiratory viral infections research
- Pneumonia and Respiratory Infections
- Cervical Cancer and HPV Research
- COVID-19 Clinical Research Studies
- Vaccine Coverage and Hesitancy
- COVID-19 epidemiological studies
- Bacterial Infections and Vaccines
- Genital Health and Disease
- COVID-19 and healthcare impacts
- COVID-19 Impact on Reproduction
- Pneumocystis jirovecii pneumonia detection and treatment
- Primary Care and Health Outcomes
- Public Health Policies and Education
- Reproductive tract infections research
- Health Policy Implementation Science
- Streptococcal Infections and Treatments
- Data-Driven Disease Surveillance
- Hepatitis B Virus Studies
- Immunodeficiency and Autoimmune Disorders
- Long-Term Effects of COVID-19
- Antimicrobial Resistance in Staphylococcus
- Kawasaki Disease and Coronary Complications
- SARS-CoV-2 and COVID-19 Research
- Health Sciences Research and Education
University of Rochester
2015-2024
University of Rochester Medical Center
2014-2024
PsiOxus Therapeutics (United Kingdom)
2024
Northwestern University
2023
University of California, San Diego
2023
Manufacturing Advocacy & Growth Network (United States)
2023
New York State Department of Health
2009-2022
New Mexico Department of Health
2021-2022
Emory University
2020-2022
Atlanta Research and Education Foundation
2022
Since SARS-CoV-2, the novel coronavirus that causes disease 2019 (COVID-19), was first detected in December (1), approximately 1.3 million cases have been reported worldwide (2), including 330,000 United States (3). To conduct population-based surveillance for laboratory-confirmed COVID-19-associated hospitalizations States, COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) created using existing infrastructure of Influenza (FluSurv-NET) (4) and Respiratory Syncytial Virus...
In early 2000, a protein-polysaccharide conjugate vaccine targeting seven pneumococcal serotypes was licensed in the United States for use young children.We examined population-based data from Active Bacterial Core Surveillance of Centers Disease Control and Prevention to evaluate changes burden invasive disease, defined by isolation Streptococcus pneumoniae normally sterile site. Serotyping susceptibility testing isolates were performed. We assessed trends using geographic areas with...
Changes in invasive pneumococcal disease (IPD) incidence were evaluated after 7 years of 7-valent conjugate vaccine (PCV7) use US children.Laboratory-confirmed IPD cases identified during 1998-2007 by 8 active population-based surveillance sites. We compared overall, age group-specific, syndrome-specific, and serotype group-specific 2007 with that 1998-1999 (before PCV7) assessed potential coverage new formulations.Overall PCV7-type declined 45% (from 24.4 to 13.5 per 100,000 population) 94%...
The rate of bacterial meningitis declined by 55% in the United States early 1990s, when Haemophilus influenzae type b (Hib) conjugate vaccine for infants was introduced. More recent prevention measures such as pneumococcal and universal screening pregnant women group B streptococcus (GBS) have further changed epidemiology meningitis.
Five of seven serotypes in the pneumococcal conjugate vaccine, introduced for infants United States 2000, are responsible most penicillin-resistant infections. We examined effect this vaccine on invasive disease caused by resistant strains.
Abstract Background Currently, the United States has largest number of reported coronavirus disease 2019 (COVID-19) cases and deaths globally. Using a geographically diverse surveillance network, we describe risk factors for severe outcomes among adults hospitalized with COVID-19. Methods We analyzed data from 2491 laboratory-confirmed COVID-19 between 1 March–2 May 2020, as identified through Coronavirus Disease 2019–Associated Hospitalization Surveillance Network, which comprises 154...
COVID-NET conducts population-based surveillance for laboratory-confirmed COVID-19-associated hospitalizations in 99 counties † 14 states (California, Connecticut, Colorado, Georgia, Iowa, Maryland, Michigan, Minnesota, New Mexico, York, Ohio, Oregon, Tennessee, and Utah), representing all 10 U.S. Department of Health Human Services regions (2,3).Laboratory-confirmed COVID-19associated among residents a predefined catchment area who had positive SARS-CoV-2 molecular test during...
Invasive pneumococcal disease declined among children and adults after the introduction of pediatric heptavalent conjugate vaccine (PCV7) in 2000, but its effect on meningitis is unclear.We examined trends from 1998 through 2005 using active, population-based surveillance data eight sites United States. Isolates were grouped into PCV7 serotypes (4, 6B, 9V, 14, 18C, 19F, 23F), PCV7-related (6A, 9A, 9L, 9N, 18A, 18B, 18F, 19B, 19C, 23A, 23B), non-PCV7 (all others). Changes incidence assessed...
BackgroundSerotype 19A invasive pneumococcal disease (IPD) increased annually in the United States after introduction of 7-valent conjugate vaccine (PCV7). To understand this increase, we characterized serotype isolates recovered during 2005
Annual estimates of the influenza disease burden provide information to evaluate programs and allocate resources. We used a multiplier method with routine population-based surveillance data on hospitalization in United States correct for under-reporting estimate seasons after 2009 pandemic. Five sites Influenza Hospitalization Surveillance Network (FluSurv-NET) collected frequency sensitivity testing during two under-detection. Population-based rates influenza-associated Intensive Care Unit...
In January 2005, a quadrivalent (serogroups A, C , Y, and W-135) meningococcal conjugate vaccine was licensed for use in adolescents. This report describes the epidemiologic features of disease United States from 1998 through December 2007, before during implementation adolescent vaccination.Data were collected active surveillance invasive Neisseria meningitidis conducted Active Bacterial Core (ABCs) sites 1998-2007. Isolates cases serogrouped at ABCs site confirmed Centers Disease Control...
Pregnant women might be at increased risk for severe coronavirus disease 2019 (COVID-19) (1,2). The COVID-19-Associated Hospitalization Surveillance Network (COVID-NET) (3) collects data on hospitalized pregnant with laboratory-confirmed SARS-CoV-2, the virus that causes COVID-19; to date, such have been limited. During March 1-August 22, 2020, approximately one in four aged 15-49 years COVID-19 was pregnant. Among 598 COVID-19, 54.5% were asymptomatic admission. 272 who symptomatic hospital...
Abstract Background Data on risk factors for coronavirus disease 2019 (COVID-19)–associated hospitalization are needed to guide prevention efforts and clinical care. We sought identify independently associated with COVID-19–associated hospitalizations. Methods Community-dwelling adults (aged ≥18 years) in the United States hospitalized laboratory-confirmed COVID-19 during 1 March–23 June 2020 were identified from COVID-19–Associated Hospitalization Surveillance Network (COVID-NET), a...
hospital admissions are subject to lag.
Abstract Background The severity of the 2017–2018 influenza season in United States was high, with A(H3N2) viruses predominating. Here, we report vaccine effectiveness (VE) and estimate number vaccine-prevented influenza-associated illnesses, medical visits, hospitalizations, deaths for season. Methods We used national age-specific estimates coverage disease burden. estimated VE against medically attended reverse-transcription polymerase chain reaction–confirmed virus infection ambulatory...
OBJECTIVES Describe population-based rates and risk factors for pediatric severe coronavirus disease 2019 (COVID-19) (ie, ICU admission, invasive mechanical ventilation, or death). METHODS During March 2020 to May 2021, the COVID-19–Associated Hospitalization Surveillance Network identified 3106 children hospitalized with laboratory-confirmed acute respiratory syndrome 2 infection in 14 states. Among 2293 primarily admitted COVID-19, multivariable generalized estimating equations generated...
Two pneumococcal vaccines are currently licensed for use in the United States: 13-valent conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer Inc.]) and 23-valent polysaccharide (PPSV23 [Pneumovax 23, Merck Co., Inc.]). The Advisory Committee on Immunization Practices (ACIP) recommends that dose PCV13 be followed by PPSV23 all adults aged ≥65 years who have not previously received persons ≥2 at high risk disease because underlying medical conditions...
<h3>Importance</h3> Racial and ethnic minority groups are disproportionately affected by COVID-19. <h3>Objectives</h3> To evaluate whether rates of severe COVID-19, defined as hospitalization, intensive care unit (ICU) admission, or in-hospital death, higher among racial compared with non-Hispanic White persons. <h3>Design, Setting, Participants</h3> This cross-sectional study included 99 counties within 14 US states participating in the COVID-19–Associated Hospitalization Surveillance...
The first U.S. case of COVID-19 attributed to the Omicron variant SARS-CoV-2 (the virus that causes COVID-19) was reported on December 1, 2021 (1), and by week ending 25, 2021, predominant circulating in United States.* Although COVID-19-associated hospitalizations are more frequent among adults,† can lead severe outcomes children adolescents (2). This report analyzes data from Coronavirus Disease 19-Associated Hospitalization Surveillance Network (COVID-NET)§ describe (aged 0-11 years)...
Clinical trials of COVID-19 vaccines currently authorized for emergency use in the United States (Pfizer-BioNTech, Moderna, and Janssen [Johnson & Johnson]) indicate that these have high efficacy against symptomatic disease, including moderate to severe illness (1-3). In addition clinical trials, real-world assessments vaccine effectiveness are critical guiding policy building confidence, particularly among populations at higher risk more from COVID-19, older adults. To determine three...
The B.1.1.529 (Omicron) variant of SARS-CoV-2, the virus that causes COVID-19, has been predominant circulating in United States since late December 2021.* Coinciding with increased Omicron circulation, COVID-19-associated hospitalization rates rapidly among infants and children aged 0-4 years, a group not yet eligible for vaccination (1). Coronavirus Disease 19-Associated Hospitalization Surveillance Network (COVID-NET)† data were analyzed to describe hospitalizations U.S. years March 2020....
Beginning the week of December 19-25, 2021, B.1.1.529 (Omicron) variant SARS-CoV-2 (the virus that causes COVID-19) became predominant circulating in United States (i.e., accounted for >50% sequenced isolates).* Information on impact booster or additional doses COVID-19 vaccines have preventing hospitalizations during Omicron predominance is limited. Data from COVID-19-Associated Hospitalization Surveillance Network (COVID-NET)† were analyzed to compare COVID-19-associated hospitalization...